In tablet manufacturing lines handling veterinary APIs with a particle size distribution in the 10–75 µm D90 range, wet granulation is preferred over direct compression when the active substance exhibits poor flow, low bulk density, or segregation tendency after dry mixing. A starting formulation for an immediate-release tablet containing 100 mg Douling Powder per 500 mg core uses 20.0% w/w active, 35.0% w/w lactose monohydrate, 32.0% w/w microcrystalline cellulose, 5.0% w/w crospovidone, 2.5% w/w povidone K30, and 0.5% w/w magnesium stearate. Granulation is performed in a 600 L high-shear mixer at impeller tip speed 5–8 m/s and chopper speed 1500–3000 rpm, with purified water added to a wet mass end point of 45–55% w/w; the wet granules are dried in a fluid-bed dryer at inlet air temperature 55–65 °C until loss on drying reaches 2.0–3.5% w/w. Milling through a 0.8 mm screen is followed by final blending in a 300 L diffusion mixer for 15 min. Blend uniformity is confirmed by stratified sampling according to USP 905, and finished-tablet uniformity of dosage units is released using USP 905 and Ph. Eur. 2.9.40 with acceptance value AV ≤ 15. Tablet compression is run on a rotary press at 10–20 kN to achieve hardness 60–100 N and friability below 1.0% w/w when tested according to Ph. Eur. 2.9.7 and USP 1216. Disintegration is tested in water at 37 °C using Ph. Eur. 2.9.1 apparatus and must complete within 15 min. Particle size of the milled granules is checked by laser diffraction per ISO 13320:2020, and elemental impurities are controlled under ICH Q3D. Production-scale failure modes include capping at compression forces above 22 kN, punch filming when granule moisture exceeds 3.5% w/w, and blend segregation if the API-to-excipient particle size ratio exceeds 3:1. Operational boundary for direct compression trials is relative humidity below 60%; above this level, lactose monohydrate may adsorb surface moisture and reduce flow. Terminal finished product types produced on this line include uncoated immediate-release tablets, scored tablets for small-animal dose adjustment, and film-coated tablets where a coating layer of 3.0–5.0% w/w is applied in a pan coater at 45–55 °C bed temperature.

What Limits Terminal Sterilization of Aqueous Douling Powder Injection Solutions?

Aqueous injectable products manufactured from Douling Powder require forced-degradation screening before terminal sterilization is selected, because the critical process boundary is the intersection of pH-dependent hydrolysis, osmolality, and subvisible particle formation. A working concentration of 50 mg/mL active corresponds to 5.0% w/v in water for injection; this concentration cannot be assumed to survive autoclaving without data confirming assay loss ≤ 2.0% and total related substances ≤ 1.0% after exposure to 121 °C for 15 min at an F0 value ≥ 12 min. When thermal stability is inadequate, the solution is processed by aseptic filtration through a 0.22 µm PVDF membrane filter inside an ISO 5 unidirectional airflow filling line, with filter integrity tested before and after filtration by bubble point or diffusion according to the filter manufacturer protocol and sterility verified under USP 71. Formulation development uses a buffered vehicle at pH 3.5–5.5, adjusted with hydrochloric acid or sodium hydroxide; osmolality is brought to 280–320 mOsm/kg with sodium chloride or mannitol, and dissolved oxygen is reduced by nitrogen sparging to ≤ 2.0 mg/L if oxidative sensitivity is detected in forced degradation. Subvisible particulate matter in filled vials is controlled according to Ph. Eur. 2.9.19 and USP 788, with limits for containers ≥ 100 mL of ≤ 25 particles per mL at ≥ 10 µm and ≤ 3 particles per mL at ≥ 25 µm. Endotoxin levels are validated against Ph. Eur. 2.6.14 or USP 85. The finished pack configuration is commonly 50 mL or 100 mL Type I amber glass vials sealed with bromobutyl rubber stoppers and aluminum flip-off caps. Terminal products include single-dose intravenous or subcutaneous injections and multi-dose injectable solutions only when preservative efficacy testing under Ph. Eur. 5.1.3 demonstrates adequate antimicrobial preservation without incompatibility with the active substance. Operational boundaries include exclusion of terminal moist-heat sterilization when pH drift exceeds ± 0.2 pH units during hold-time studies, avoidance of oxygen-permeable container components if oxidative degradation exceeds 0.5% total impurities, and rejection of any filling campaign in which the pre-filtration bioburden exceeds 10 CFU/100 mL before sterilizing filtration.

Capsule and sachet powder formats for Douling Powder are manufactured by dry granulation when direct compression or direct filling is not possible due to poor flow, with roller compaction at roll pressure 30–60 kN and gap 1.0–2.0 mm producing ribbons milled to granules with D50 200–500 µm. The active addition ratio is determined by the final unit dose; a 25 mg strength capsule with a 180 mg fill mass uses 13.9% w/w active, a 100 mg strength with 250 mg fill uses 40.0% w/w, and a 500 mg strength with 600 mg fill uses 83.3% w/w, after potency adjustment on an as-is basis. Powder uniformity is verified with USP 905 for finished capsules and Ph. Eur. 2.9.40 for single-dose preparations. Capsule dissolution is run using USP 711 Apparatus II at 50–75 rpm in 900 mL of 0.1 M hydrochloric acid or pH 6.8 phosphate buffer depending on the target species and the biopharmaceutical classification of the active; acceptance is not less than 75% (Q) dissolved at 45 min unless an authorized specification justifies otherwise. The filling operation is conducted on an intermittent-motion capsule filler with fill weight control at ± 3.0% and empty-shell detection by vacuum or capacitance sensors. Batch-to-batch variance is commonly observed when the roller-compacted granule fraction below 100 µm exceeds 20.0% w/w, causing inconsistent fill density and higher weight variation. Terminal finished product types include hard gelatin capsules, hydroxypropyl methylcellulose capsules intended for vegetarian preference markets, and unit-dose foil-laminate sachets containing 1 g, 5 g, or 25 g powder for direct oral administration after reconstitution in drinking water or milk replacer.

Medicated Feed Premix Homogeneity, Carryover Limits, and Blender Performance Indicators

Premix production of Douling Powder for medicated feed is a low-dose mixing operation in which the primary process conflict is between the target active concentration in final feed and the analytical homogeneity of the concentrated premix. The active addition ratio in a concentrated premix typically ranges from 2.0% w/w to 10.0% w/w on a carrier such as lactose monohydrate, wheat middlings, or calcium carbonate, and the premix is subsequently diluted into complete feed at rates of 0.5–10 kg/tonne. For example, a 5.0% w/w Douling Powder premix incorporated at 2.0 kg/tonne delivers 100 mg/kg active in the final feed; this calculation is species-dose dependent and must be confirmed against the approved veterinary medicinal product file. Mixing validation is conducted in a double-ribbon mixer with 50–70% working fill volume and mixing time determined by sampling at 2 min, 5 min, 10 min, and 20 min; the coefficient of variation across 10–20 samples should remain ≤ 5.0% for the active assay. Segregation and dusting are controlled by matching particle sizes; a critical process limit is that the API D90 and carrier D90 should differ by less than 3:1, otherwise static adhesion and percolation can increase CV above 10%. Carrier moisture content below 12.0% w/w is used to avoid clumping, and where the premix is pelleted, post-conditioning temperature should not exceed 75 °C unless forced degradation of the active at 80 °C for 24 h demonstrates recovery ≥ 98.0%. Carryover and cleaning validation follow the general GMP principles of EU GMP Annex 15 and medicated feed controls under Regulation (EU) 2019/4; analytical methods using LC-MS/MS are expected to quantitate active residues in flush material, with limits established from the lowest intended dose and the daily feed intake of the most sensitive non-target species. Terminal finished product types include meal premix, granulated premix in 1 kg and 25 kg bags, and pelleted or extruded complete feed manufactured in integrated mills.

When Douling Powder Is Formulated into Water-Soluble Granules for Mass Medication via Drinking Water

Water-soluble granules pose the narrowest processing window because sorption of atmospheric moisture during storage can initiate caking, reduce dissolution rate, and alter delivered dose in automatic dosing pumps. The granule formulation generally contains 10.0–50.0% w/w Douling Powder, with the balance consisting of a soluble filler such as lactose monohydrate, sodium citrate, and an effervescent couple of citric acid and sodium bicarbonate in a 1.0:1.2 stoichiometric ratio; when reconstituted at 0.1–1.0 g/L in drinking water, the resulting active concentration is 10–100 mg/L depending on the designated target species and daily water consumption. Wet granulation is performed in a fluid-bed granulator with inlet air at 50–60 °C and product temperature 25–35 °C, because drying at product temperature above 40 °C may be allowed only after thermal degradation data support retention of assay and total impurities. The granulate is sieved to 150–850 µm and moisture is reduced to ≤ 2.0% w/w before packaging in aluminum foil sachets under ≤ 30% relative humidity. Dissolution performance is tested by adding a 5 g sample to 1 L water at 20 °C; complete visual dispersion should occur within 3 min with no residue on a 0.50 mm sieve, and the active assay in the drinking water should remain 90.0–110.0% of theoretical concentration after 24 h storage in the stock solution. Dosing pump compatibility limits are defined by solution viscosity below 10 mPa·s measured at 25 °C according to ISO 3219:1993 and by absence of particulates larger than 100 µm that can obstruct diaphragm pump valves. Proportioner pump calibration is documented under the manufacturer’s ISO 9001:2015 quality system, and chemical and microbiological quality of the drinking water used for reconstitution is controlled according to EU Directive 2020/2184. Terminal finished product types include water-soluble powder sachets, graduated buckets for stock solution preparation, and in-line medicator concentrates intended for swine and poultry drinking water systems.

For non-sterile liquid dosage forms such as oral drench solutions, the active is dissolved in a co-solvent system composed of 40.0–60.0% w/w propylene glycol, 10.0–30.0% w/w glycerol, and water, with active concentration typically 5.0–50.0 mg/mL or 0.5–5.0% w/v. The dissolution order is fixed: Douling Powder is first dispersed in the co-solvent under a high-shear overhead mixer at 1500–2500 rpm for 20 min, then buffer salts are added, and the batch is made to final volume with purified water at 20–25 °C. Product pH is adjusted to 4.0–6.0 based on the solubility maximum determined by shake-flask screening. The liquid is passed through a 0.45 µm polypropylene cartridge filter to reduce undissolved material, then filled into 100 mL, 250 mL, or 1 L high-density polyethylene bottles with tamper-evident caps. Dosing accuracy of the final product is checked by delivered dose uniformity under Ph. Eur. 2.9.5 or USP 905, and viscosity is controlled below 50 mPa·s at 25 °C using ISO 3219:1993 to ensure repeatable pouring from multidose containers. Microbiological quality for non-sterile oral liquids is assessed according to Ph. Eur. 2.6.12 or USP 61, with acceptance for TAMC ≤ 1000 CFU/g and TYMC ≤ 100 CFU/g when specified for veterinary oral products. Production-scale limitations include precipitation of the active when the aqueous phase exceeds 60.0% w/w at low pH, gelling or crystal growth during storage below 5 °C, and photodegradation risk if the solution is filled into white translucent polyethylene containers without light-protective secondary packaging. Terminal finished product types include oral drench solutions for cattle and sheep, liquid feed drinking water additives, and concentrated oral solutions for swine administered through proportioner pumps.